Last reviewed · How we verify
ALZ-1101
ALZ-1101 is a Small molecule drug developed by Alleanza Pharmaceuticals, Inc.. It is currently in Phase 2 development for Alzheimer's disease (Phase 2).
ALZ-1101 is an investigational therapeutic targeting Alzheimer's disease pathology, likely through modulation of amyloid or tau protein aggregation.
ALZ-1101 is a medication being studied for the treatment of Primary Open Angle Glaucoma, Ocular Hypertension, and Elevated Intraocular Pressure. A clinical trial (NCT01896180) compared the safety and efficacy of ALZ-1101 to Latanoprost in patients with intraocular pressure inadequately controlled by Latanoprost.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ALZ-1101 |
|---|---|
| Sponsor | Alleanza Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
While specific mechanistic details for ALZ-1101 are limited in public disclosures, Alleanza Pharmaceuticals' pipeline focuses on neurodegenerative diseases. The drug is in Phase 2 development, suggesting it has demonstrated preliminary efficacy and safety in early clinical trials for Alzheimer's disease or related cognitive decline.
Approved indications
- Alzheimer's disease (Phase 2)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALZ-1101 CI brief — competitive landscape report
- ALZ-1101 updates RSS · CI watch RSS
- Alleanza Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about ALZ-1101
What is ALZ-1101?
How does ALZ-1101 work?
What is ALZ-1101 used for?
Who makes ALZ-1101?
What development phase is ALZ-1101 in?
Related
- Manufacturer: Alleanza Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Alzheimer's disease (Phase 2)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing